Research programme: TNF-alpha converting enzyme inhibitors - Bristol-Myers Squibb
Alternative Names: DPC-A38088Latest Information Update: 18 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 20 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th-ACS-2005) have been added to the pharmacokinetics section ,
- 13 Sep 2004 Data presented at the 228th American Chemical Society National Meeting (228th-ACS-2004) have been added to the pharmacokinetics section
- 17 Feb 2004 Preclinical trials in Rheumatoid arthritis in USA (PO)